drugset / Trial / NCT06723015

Tau PET Outcomes With Anti-amyloid Immunotherapies

NCT06723015

Phase 2 Enrolling by invitation 135 enrolled Mayo Clinic
Non-randomizedParallel-groupOpen-labelOther

Summary

This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.

Timeline

Start
2025-11-04
Primary completion
2028-08
Completion
2028-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Flortaucipir F18 Diagnostic / imaging agent 370 mbq